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Inhibitors Downstream of
the Coronary Occlusion:
The “Highway” to PeripheryWe read with interest the study of Eitel et al. (1) about the AIDA
STEMI (Abciximab i.v. Versus i.c. in ST-Elevation Myocardial
Infarction) trial, regarding infarct size. The study shows an inter-
esting result: Microvascular Obstruction (MO) and infarct size did
not signiﬁcantly differ between intravenous versus intracoronary
administration of abciximab.
The glycoprotein IIb/IIIa inhibitors (GPI) can be effective only
on fresh thrombus, lowering the thrombus burden and dis-
aggregating embolized platelet microaggregates. Recently, 1 study
(2) has shown the presence of old thrombus in 40% of patients with
ST-segment elevation myocardial infarction. This would be one of
the mechanisms underlying the inconsistent beneﬁt of GPIs.
Another potential mechanism might be the lack or the short
contact time between the GPI, thrombus, and embolized micro-
aggregates. In the study of Bellandi et al. (3), with downstream
GPI administration, a signiﬁcant beneﬁcial effect on MO and
infarct size occurred. In the INFUSE-AMI (Intracoronary
Abciximab Infusion and Aspiration Thrombectomy in Patients
Undergoing Percutaneous Coronary Intervention for Anterior ST
Segment Elevation Myocardial Infarction) trial (4), abciximab was
administered through the ClearWay catheter, which might be
equivalent with a pre-dilation. In addition, the effect of abciximab
was targeted mostly to the thrombus. There was no difference on
MO, but a modest reduction in infarct size occurred. In a study
recently published, our group used a Twin-Pass catheter for
downstream and intrathrombus GPI delivery (5). There were no
signiﬁcant differences on MO and infarct size, but there was
a trend toward better MO results with intracoronary GPI. The
downstream administration of GPIs achieves higher local drug
concentrations and a longer contact on microaggregates.
The cases with old thrombus could be associated with more
extensive MO (2). These patients may beneﬁt from intracoronary
thrombolytic drugs, as shown by Sezer et al. (6).*Adrian C. Iancu, MD, PhD
Camelia Ober, MD
*“Niculae Stancioiu” Heart Institute
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We agree that timing of glycoprotein IIb/IIIa inhibitor adminis-
tration is an important factor. A recent meta-analysis comparing
intravenous versus intracoronary abciximab application found
a trend toward a greater efﬁcacy with intracoronary abciximab with
an ischemic time <3 h (2). This ﬁnding may be partly related to the
fast-evolving process of thrombus formation during an acute
coronary occlusion. Indeed, a recent study demonstrated that
platelet and ﬁbrin contents of the occlusive thrombus are highly
dependent on ischemia time, which may have a direct impact on
the efﬁcacy of glycoprotein IIb/IIIa inhibitors (3). However, in the
AIDA STEMI trial (Abciximab i.v. Versus i.c. in ST-elevation
Myocardial Infarction) and the cardiac magnetic resonance sub-
study there was no beneﬁt with intracoronary abciximab application
even in patients reperfused early after symptom onset (<3 h) (1,4).
We also agree that the short contact time between the glyco-
protein IIb/IIIa inhibitor with plaque/thrombus components might
have inﬂuenced the results of our study. In the AIDA STEMI trial
abciximab was injected through the guiding catheter after wiring of
the infarct-related artery (1,4). Although easy to implement in
clinical practice, this way of delivery may be suboptimal in selected
patients due to inadequate thrombus penetration of abciximab and
possible retrograde washout into the ascending aorta. Novel
application systems such as dedicated perfusion catheters may exert
superior efﬁcacy by maintaining a high local abciximab concen-
tration, thereby providing an optimal contact between the plaque/
thrombus components and the drug. However, it is important to
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482note that in INFUSE-MI (Intracoronary Abciximab Infusion and
Aspiration Thrombectomy in Patients Undergoing Percutaneous
Coronary Intervention for Anterior ST-Segment Elevation
Myocardial Infarction) even with the use of a dedicated local drug
delivery balloon in high-risk patients with anterior ST-segment
elevation myocardial infarction presenting early (<4 h) the
magnitude of the absolute infarct size reduction with intracoronary
abciximab versus no abciximab was modest and was not ac-
companied by other markers of reperfusion success (5). Therefore,
further studies are needed to clarify the additional value of super-
selective intracoronary delivery of abciximab.*Ingo Eitel, MD
Steffen Desch, MD
Holger Thiele, MD
*University of Leipzig - Heart Center
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Ruwald et al. (1) performed a non–pre-speciﬁed subgroup analysis
of patients enrolled in MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial with Cardiac Resynchronization
Therapy) who received either carvedilol or metoprolol. They
concluded that carvedilol was associated with a 30% reduction in
hospitalization for heart failure or death when compared to meto-
prolol (1). However, they have not emphasized the following:
1. The presence of signiﬁcant differences in baseline charac-
teristics that heavily favor carvedilol. In the metoprolol
group and compared to the carvedilol group there were more
men (79% vs. 71%) (2), patients were older (65 vs. 63.5 years
of age) (3), and patients had higher prevalences of ischemicetiology (65% vs. 47%) (4) and prior myocardial infarction
(53% vs. 37%), with a higher burden of ischemia as evident
by higher prevalences of coronary artery bypass (34% vs.
25%) as well as non-coronary artery bypass revascularization
(32% vs. 24%). Moreover, they had signiﬁcantly more
hospitalization in the prior year (53% vs. 43%) (5). In
addition, they had a signiﬁcantly higher prevalence of
systolic blood pressure >140 mm Hg (21% vs. 16%). All of
these factors combined could have heavily inﬂuenced the
outcomes in favor of carvedilol.
2. The authors stated that 12% of those on metoprolol used the
metoprolol tartrate preparation. Considering the absence of
data from randomized trials documenting improvement in
survival or reduction of hospitalization with metoprolol
tartrate (6), these patients should have been excluded from
analysis.
3. The causes of switching from carvedilol to metoprolol need
to be ascertained. Was it because of low blood pressure? Was
there clustering of events in these patients? Regardless,
patients (n ¼ 92) who were changed from 1 type to the other
should have been excluded. It is virtually impossible to place
them in either group with certainty.
In addition, comparing the low dose of beta-blockers in the
MADIT-CRT to that in either OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients
with Heart Failure) or COPERNICUS (Carvedilol Prospective
Randomized Cumulative Survival) is somewhat inappropriate as
the dose of beta-blockers is expected to be lower in hospitalized
patients and in patients with advanced heart failure.
Finally, would the authors care to speculate on a potential mech-
anism for the suggested synergistic effect of carvedilol in patients
with left bundle branch block?*Jalal K. Ghali, MD
*Department of Internal Medicine
Division of Cardiology





Please note: Dr. Ghali has in the past contributed to subgroup analysis involving
patients from MERIT-HF. He has received an honorarium for giving a lecture on
beta-blockers from AstraZenca.
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